Antimalarial drug resistance and combination chemotherapy
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Antimarial drug resistance develops when spontaneously occurring parasite mutants with reduced susceptibility are selected, and are then transmitted. Drugs for which a single point mutation confers a marked reduction in susceptibility are particularly vulnerable. Low clearance and a shallow concentration–effect relationship increase the chance of selection. Use of combinations of antimalarials that do not share the same resistance mechanisms will reduce the chance of selection because the chance of a resistant mutant surviving is the product of the per parasite mutation rates for the individual drugs, multiplied by the number of parasites in an infection that are exposed to the drugs. Artemisinin derivatives are particularly effective combination partners because (i) they are very active antimalarials, producing up to 10 000–fold reductions in parasite biomass per asexual cycle; (ii) they reduce malaria transmissibility; and (iii) no resistance to these drugs has been reported yet. There are good arguments for no longer using antimalarial drugs alone in treatment, and instead always using a combination with artemisinin or one of its derivatives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy
Meshnick, S. R., Taylor, T. E., & Kamchonwongpaisan, S. (1996) · Microbiological Reviews · doi:10.1128/mmbr.60.2.301-315.1996 · Cited by 710 · cited 1×
“The artemisinin compounds act by the haem-catalysed intraparasitic production of highly reactive carbon-centred free radicals (Meshnick et al. 1996; Kamchonwongpaisan et al. 1996).”
BackgroundPeterson, D. S., Walliker, D., & Wellems, T. E. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.23.9114 · Cited by 653
Assessment of the pharmacodynamic properties of antimalarial drugs in vivo
White, N. J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1413 · Cited by 575
Self-citationPLASMODIUM VIVAX RESISTANCE TO CHLOROQUINE?
Rieckmann, K. H., Davis, D. R., & Hutton, D. C. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91792-3 · Cited by 501
Evaluating treatment protocols to prevent antibiotic resistance
Bonhoeffer, S., Lipsitch, M., & Levin, B. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.22.12106 · Cited by 487
Impact of chloroquine resistance on malaria mortality
Trape, J.-F., Pison, G., Preziosi, M.-P., Enel, C., du Loû, A. D., Delaunay, V., Samb, B., Lagarde, E., Molez, J.-F., & Simondon, F. (1998) · Comptes Rendus de l'Académie des Sciences - Series III - Sciences de la Vie · doi:10.1016/s0764-4469(98)80009-7 · Cited by 452
Looareesuwan, S., Viravan, C., Webster, H. K., Kyle, D. E., Hutchinson, D. B., & Canfield, C. J. (1996) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1996.54.62 · Cited by 407
Cowman, A. F., Galatis, D., & Thompson, J. K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.3.1143 · Cited by 401
Chloroquine: Mechanism of drug action and resistance in plasmodium falciparum
Slater, A. F. G. (1993) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(93)90056-j · Cited by 390
Malarial haemozoin/β-haematin supports haem polymerization in the absence of protein
Dorn, A., Stoffel, R., Matile, H., Bubendorf, A., & Ridley, R. G. (1995) · Nature · doi:10.1038/374269a0 · Cited by 389
Cited by
White, N. J. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421682 · Cited by 1,248
Self-citationMefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number
Price, R. N., Uhlemann, A.-C., Brockman, A., McGready, R., Ashley, E., Phaipun, L., Patel, R., Laing, K., Looareesuwan, S., White, N. J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16767-6 · Cited by 853
Self-citationEpidemiology of drug-resistant malaria
Wongsrichanalai, C., Pickard, A. L., Wernsdorfer, W. H., & Meshnick, S. R. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00239-6 · Cited by 817
Artemisinin: mechanisms of action, resistance and toxicity
Meshnick, S. R. (2002) · International Journal for Parasitology · doi:10.1016/s0020-7519(02)00194-7 · Cited by 720
CONQUERING THE INTOLERABLE BURDEN OF MALARIA: WHAT’S NEW, WHAT’S NEEDED: A SUMMARY
BREMAN, J. G., ALILIO, M. S., & MILLS, A. (2004) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2004.71.2_suppl.0700001 · Cited by 677
Artemisinin-Based Combination Treatment of Falciparum Malaria
Nosten, F., & White, N. J. (2007) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2007.77.181 · Cited by 673
Self-citationIdentification of an antimalarial synthetic trioxolane drug development candidate
Vennerstrom, J. L., Arbe-Barnes, S., Brun, R., Charman, S. A., Chiu, F. C. K., Chollet, J., Dong, Y., Dorn, A., Hunziker, D., Matile, H., et al. (2004) · Nature · doi:10.1038/nature02779 · Cited by 622
Ashley, E. A., Pyae Phyo, A., & Woodrow, C. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30324-6 · Cited by 553
A Medicinal Chemistry Perspective on Artemisinin and Related Endoperoxides
O'Neill, P. M., & Posner, G. H. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030571c · Cited by 538
Artesunate combinations for treatment of malaria: meta-analysis
(2004) · The Lancet · doi:10.1016/s0140-6736(03)15162-8 · Cited by 538
Intercontinental Spread of Pyrimethamine-Resistant Malaria
Roper, C., Pearce, R., Nair, S., Sharp, B., Nosten, F., & Anderson, T. (2004) · Science · doi:10.1126/science.1098876 · Cited by 510
Effectiveness of Antimalarial Drugs
Baird, J. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043207 · Cited by 375
Discovery, mechanisms of action and combination therapy of artemisinin
Cui, L., & Su, X.-Z. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.68 · Cited by 371
Guerin, P. J., Olliaro, P., Nosten, F., Druilhe, P., Laxminarayan, R., Binka, F., Kilama, W. L., Ford, N., & White, N. J. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00372-9 · Cited by 357
Self-citationMutabingwa, T. K. (2005) · Acta Tropica · doi:10.1016/j.actatropica.2005.06.009 · Cited by 352
Counterfeit anti-infective drugs
Newton, P. N., Green, M. D., Fernández, F. M., Day, N. P., & White, N. J. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70581-3 · Cited by 348
Self-citationNew developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance
Price, R. N., Douglas, N. M., & Anstey, N. M. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32832f14c1 · Cited by 343
WHO Guidelines for the treatment of malaria
Kunte, R., & Kunwar, R. (2011) · Medical Journal Armed Forces India · doi:10.1016/s0377-1237(16)30022-3 · Cited by 341
History, Dynamics, and Public Health Importance of Malaria Parasite Resistance
Talisuna, A. O., Bloland, P., & D’Alessandro, U. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.1.235-254.2004 · Cited by 322
Contribution of the pfmdr1 gene to antimalarial drug-resistance
Duraisingh, M. T., & Cowman, A. F. (2005) · Acta Tropica · doi:10.1016/j.actatropica.2005.04.008 · Cited by 300
New medicines to improve control and contribute to the eradication of malaria
Wells, T. N. C., Alonso, P. L., & Gutteridge, W. E. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2972 · Cited by 298
The Drugs We Have and the Drugs We Need Against Major Helminth Infections
Keiser, J., & Utzinger, J. (2010) · Advances in Parasitology · doi:10.1016/s0065-308x(10)73008-6 · Cited by 288
Carrara, V. I., Zwang, J., Ashley, E. A., Price, R. N., Stepniewska, K., Barends, M., Brockman, A., Anderson, T., McGready, R., Phaiphun, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004551 · Cited by 281
Self-citationSynthetic peroxides as antimalarials
Tang, Y., Dong, Y., & Vennerstrom, J. L. (2004) · Medicinal Research Reviews · doi:10.1002/med.10066 · Cited by 275
Ratcliff, A., Siswantoro, H., Kenangalem, E., Maristela, R., Wuwung, R., Laihad, F., Ebsworth, E., Anstey, N., Tjitra, E., & Price, R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60160-3 · Cited by 271
Efferth, T. (2007) · Planta Medica · doi:10.1055/s-2007-967138 · Cited by 269
Brockman, A., Price, R. N., van Vugt, M., Heppner, D. G., Walsh, D., Sookto, P., Wimonwattrawatee, T., Looareesuwan, S., White, N. J., & Nosten, F. (2000) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(00)90080-4 · Cited by 185
“Nevertheless, this points to the powerful selective pressure exerted by antimalarial drugs towards the emergence of resistance through both preferential survival, and thus transmission of resistant parasites, and the much rarer selection of de novo mutants with reduced susceptibility (White, 1999).”
BackgroundSelf-citationMcGready, R., Cho, T., Keo, N. K., Thwai, K. L., Villegas, L., Looareesuwan, S., White, N. J., & Nosten, F. (2001) · Clinical Infectious Diseases · doi:10.1086/324349 · Cited by 178
Self-citationMcGready, R., Stepniewska, K., Ward, S. A., Cho, T., Gilveray, G., Looareesuwan, S., White, N. J., & Nosten, F. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0118-y · Cited by 101
Self-citationCohen, J. L., Yavuz, E., Morris, A., Arkedis, J., & Sabot, O. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-83 · Cited by 45
Essential oils of petal, leaf and stem of the antimalarial plant Artemisia annua
Goel, D., Singh, V., Ali, M., Mallavarupu, G. R., & Kumar, S. (2007) · Journal of Natural Medicines · doi:10.1007/s11418-006-0112-9 · Cited by 32
“As the malarial parasite Plasmodium falciparum have become resistant to conventional antimalarials, artemisinin formulations are the only reliable antimalarial therapies [5, 6].”
Background
Metadata
- Authors
- White, N.
- Venue
- Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences
- Publisher
- The Royal Society
- Published
- 1999-04-29
- Volume
- 354
- Issue
- 1384
- Pages
- 739-749
- ISSN
- 0962-8436 (ISSN-L)
- 1471-2970
- OpenAlex
- W2142999550
- Cited by
- 477
- References
- 48
- FWCI
- 23.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.